From July 1, 2021 to September 30, 2021, the company has repurchased 2,886,900 shares, representing 0.52% for CNY 29.81 million. With this, the company has completed the repurchase of 19,086,325 shares, representing 3.39% for CNY 184.47 million under the buyback announced on February 2, 2021.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
25.67 CNY | -0.73% | -4.04% | +50.03% |
May. 13 | Lingrui Pharma Gets Green Light to Market Type 2 Diabetes Drug | MT |
Apr. 25 | Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+50.03% | 2.02B | |
+45.15% | 6.34B | |
-14.00% | 4.61B | |
+9.54% | 3.39B | |
-8.99% | 3.29B | |
-6.97% | 1.73B | |
-0.31% | 1.67B | |
+50.00% | 1.63B | |
-10.61% | 1.59B | |
+36.19% | 1.34B |
- Stock Market
- Equities
- 600285 Stock
- News Henan Lingrui Pharmaceutical Co., Ltd.
- Tranche Update on Henan Lingrui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 2, 2021.